clinical trial · NCT03630315
CLN-0046: Treatment of AMD Subjects With OTX-TKI
Neovascular Age-related Macular DegenerationOTX-TKIOTX-TKIOTX-TKIOTX-TKIAnti-VEGFOTX-TKIAnti-VEGF
brief summary
To evaluate the safety, tolerability and efficacy of OTX-TKI for intravitreal use, in subjects who have neovascular age-related macular degeneration (AMD).
started
Feb 18, 2019
primary completion
Jan 10, 2024
completion
Jan 10, 2024
last updated
Jul 10, 2024
detailed description
A multi-center, dose escalation, Phase 1, safety, tolerability and efficacy study to evaluate three dose groups of the OTX-TKI implant to treat subjects with a diagnosis of primary subfoveal neovascularization secondary to AMD.
official title
A Phase 1 Open-Label, Dose Escalation Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol